Beijing's first pilot variety approved, rare disease innovative drug "cross-border segmented production" globally synchronized listing.

Recently, Johnson Pharmaceutical Limited's injection of eculizumab received approval from the National Medical Products Administration for cross-border segmented production pilot, marking the innovative product's simultaneous global launch. It is also the first biopharmaceutical product in the country to treat "generalized myasthenia gravis" in adolescents aged 12 and above. According to the city's drug regulatory authority, the raw material for this product is produced domestically, while formulation and packaging are done overseas, making it the city's first approved biopharmaceutical segmented production pilot.